Max Herrmann

Consultant & CFO

Max is an experienced Chief Financial Officer with more than 20 years experience in scientific and financial aspects of the pharmaceutical industry including roles in both industry and investment banking. He was until recently CFO of the AIM-listed RNAi company Silence Therapeutics plc, where he raised £11m, and prior to that was CFO at Intercytex Group plc. After being appointed as Financial Controller at Onyx Pharmaceuticals, where he worked on its $35m NASDAQ IPO, Max spent over a decade in the City as a pharma and biotech investment analyst, where he covered a range of companies and was involved in transactions raising over $200m. Max is a Chartered Accountant and has a degree in Microbiology from the University of Kent.

 

Funding Partners: